DOCSLIB.ORG

The Endocannabinoid System in Health and Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Endocannabinoid System in Health and Disease Bones and Joints: The Endocannabinoid System in Health and Disease Joel Ehrenkranz MD Utah Dept. of Health Product Review Board Utah Dept. of HealthMedical Cannabis Compassionate Use Board Nothing to disclose Learning Objectives • Review the endocannabinoid system • physiology • pathology • pharmacology • Discuss the principles of medical cannabis prescribing • indications • dosing • toxicity • monitoring • Provide guidance on regulatory compliance with Utah Medical Cannabis Act A Woman With Congenital Endocannabinoid Excess 66 year old female with bilateral pantrapezial osteoarthritis • underwent trapeziectomy • no postoperative pain or analgesia use • Past medical history • Age 65: painless osteoarthritis of the hip • Longstanding memory lapses • forgets words in mid-sentence • misplaces keys • Never panics • Surgical history • No analgesia requirement • hip replacement • varicose vein and dental procedures • painless injuries • laceration suturing • fracture left wrist • cuts and burns • Family and Social History • Father and son: little requirement for pain medications • Physical Exam • optimistic and happy affect • 0/21 on generalized anxiety questionnaire A Woman With Congenital Endocannabinoid Excess Due to FAAH Gene Deletion FAAH Pseudogene Deletion: Molecular Pathology X Humans Have Used Cannabis for Millenia. Chromatograms of the ancient cannabis and the inner charred surface of the wooden brazier M25:2. (A) Total ion current (TIC) chromatogram of the ancient cannabis from the Jiayi Cemetery, Turpan showing the presence of C16:0 (hexadecanoic acid), C18:0 (octadecanoic acid), and CBN. (B) Chromatogram in select ion mode (SIM) of the ancient cannabis showing several cannabinoids: CBN, cannabidiol (CBD) and cannabicyclol (CBL); (C) TIC chromatogram of the internal charred fragment of wooden brazier M25:2 from the Jirzankal Cemetery; and (D) SIM chromatogram of the internal charred fragment of wooden brazier M25:2 Eminence-Based Medicine: Cannabis Ethnopharmacology “The Scythians take kannabis seed, creep in under the felts, and throw it on the red-hot stones. It smolders and sends up such billows of steam-smoke that no Greek vapor bath can surpass it. The Scythians howl with joy in these vapor-baths, which serve them instead of bathing, for they never wash their bodies with water.” Herodotus, A. D. Godley. Trans. The Histories (Harvard Univ. Press, 1920). Heat converts THCA to THC. The Endocannabinoid System endocannabinoids endocannabinoid receptors downstream intracellular signaling • TRPV1 : vanilloid receptor: involved in pain and temperature sense Cellular signaling: • GPR 18, 19, 55, 119: • cAMP + MAPK orphan nuclear receptors • arrestins • PPAR α and γ • ceramide Endocannabinoid Receptors • CB1 receptor • Present in all chordates. • CB2 receptor • Human CR1 gene located on chromosome 6q15 • CNR2 gene located on 1p36.11 • Widely expressed in multiple tissues • Arose as CNR1 gene duplication 400 MYA • Mediates psychoactive effects • RNA expressed in: • lymphocytes • lymph nodes • spleen • tonsils • appendix • bone • microglia • Increased protein expression • MS and ALS • experimental peripheral neuropathy Endocannabinoids and Sepsis Endocannabinoids are involved in the host response to sepsis. • Endotoxin: • Increases endocannabinoid receptors gene transcription • Increases intracellular endocannabinoid levels • CB1 receptors • Activated by anandamide from macrophages and 2-AG from platelets • Contributes to hypotension • CB2 receptors • Decrease innate immune response • reduces generation of pro-inflammatory cytokines • increases bacterial phagocytosis • Phytocannabinoids • Have anti-bacterial, anti-viral, and anti-parasitic activity • Bind to nonribosomal antibiotic peptides Cannabinoids in Diabetic Ketoacidosis endocannabinoid In adults with T1DM: cannabis use within the previous 12 months was associated with an increased risk of DKA compared with no cannabis use. JAMA Internal Medicine November 5, 2018 5, 2018 Clinical Implication literatureClinical Implications • No literature on chronic cannabis use and type 1 diabetes. • No literature on cannabis’ role in DKA. • on chronic cannabis use and type 1 diabetes. Cell Metabolism 2018 • No literature on cannabis’ role in DKA. Endocannabinoids and Trauma Orthopedic literature: fractures of long bones, when associated with traumatic brain injuries, frequently heal with excessive callus and faster than normal. • CNS injury elevates endocannabinoids. • Endocannabinoids regulate bone growth and remodeling • Osteoblasts, osteoclasts, osteocytes, fibroblasts, chondrocytes contain: • endocannabinoids and endocannabinoid mimetics (lipoamines: oleoyl serine) • enzymes for endocannabinoid synthesis and degradation Endocannabinoids and Bone Cannabis Effects on Bone: Epidemiology • UK heavy recreational cannabis users – Self-reported cannabis use – Decreased hip and lumbar spine BMD – Increased fracture rate – Increased type 1 C-teleopeptides and procollagen – Decreased bone mineral density – Secondary to decreased BMI • US NHANES data – Adults ages 20-59 – No association of self-reported cannabis use with bone mineral density – Decreased BMI Endocannabinoids: Human Bone Pathology • Chrondocytes from osteoarthritic joints – Express CNR1 and 2, TRPR 1, GPR 18 and 55 – Expression does not correlate with amount of joint damage • Synovial biopsies in patients with osteoarthritis and rheumatoid arthritis – Express CNR1 and 2 RNA and protein – Contain increased levels of endocannabinoids – Not seen in controls • Gene Linkage studies – CNR2 SNP’s linked to osteoporosis in some human populations – 1p36 (location of CNR2 gene) associated with decreased bone density Cannabidiol (CBD) Pharmacology and toxicology • weak CB1 and CB2 antagonist • ? blocks clearance of endocannabinoids • lacks psychoactive effects • does not cross-react in cannabinoid immunoassays. • In rats: – decreases inflammatory response to disc injury – decreases inflammation in experimental arthritis models – improves fracture healing • In humans: – decreases inflammation in vitro • peripheral neuropathy • periodontitis • hepatic ischemia Endocannabinoid Mimetics • Endocannabinoid receptor ligands found in non-Cannabis plants – Liverwort: CB1 agonist – Cornflower: CB2 agonist • Cannabinoid receptor ligands present in foods – β-caryophyllene: CB2 agonist • blocks cisplatin nephrotoxicity in a mouse model • inhibits inflammation in mouse model of inflammatory colitis • in mouse bone marrow cultures, – increases osteoblastic mineralization – decreases osteoclastogenesis and adipogenesis – Guineensine: (black pepper): decreases 2-AG reuptake – Falcarinol (carrots, parsley, celery): CB1 antagonist • Reloxifene / SERMS – CB2 agonist: may account for anti-osteoporotic effects • Pregnenolone: - CB1 antagonist: blunts psychoactive effects of THC Medical Cannabis Indications Conclusive or substantial evidence: • chronic pain • chemotherapy-induced nausea and vomiting • spasticity with multiple sclerosis • Lennox-Gastaut and Dravet syndromes Moderate evidence of effect • sleep disturbance Limited evidence of effect • appetite and weight gain • PTSD • social anxiety No or insufficient evidence • cancer • epilepsy • ALS, Huntington’s, Parkinson’s • irritable bowel Abrams D. Eur. J. Int M. 2018 • Opiate addiction “The absence of evidence does not mean of absence” www.pnas.org/cgi/doi/10.1073/pnas.1903434116 Cannabis availability ~ opiate overdoses Medical Cannabis Contraindications • contraindicated in pregnancy and lactation • contraindicated in heart disease – angina due to tachycardia – hypotension due to THC • relative contraindication < 21 years old • in addiction and dependency (controversial) • smoking and vaping in patients with COPD and asthma. Medical Cannabis Recommending • Preferred formulation: – Nabiximols: oromucosal whole plant extract – CBD-predominant chemovars with the smallest amount of THC • optimal improvement in symptom control and quality of life • fewest adverse events European Journal of Internal Medicine 49 (2018) 12–19 Cannabis Recommending: Standards of Care • Utah State Dept. of Health Requirements – Medical cannabis program will launch in early 2020. • 7 dispensaries state-wide • 18 Dept. of Health offices will fill medical cannabis recommendations. – Registered cannabis recommender • 4 hours of continuing medical education – Compassionate Use Board • Medical cannabis recommending – identical to prescribing of other controlled drugs – review of prior medical records if available – comprehensive history and physical – discussion of the pros and cons of cannabis – plans for appropriate follow-up care – proper documentation of the consultation – Communicate with other care-givers. Cannabis Toxicology: Point-of-Care Drug Testing • Driving / Safety Sensitive Operations • should be avoided for 4 h after inhaled cannabis use • 6 h after ingested cannabis use • 8 h if euphoria was experienced • safety-sensitive industries (aviation): no use within 28 days of work • Urinary cannabinoids • presence of cannabinoids persists for days to weeks • easy to convert positive to negative • Oral Fluid cannabinoids • present for 1-2 hours after inhalation or ingestion • brushing teeth removes cannabinoids from oral fluid • uninterpretable in patients with dentures • Serum cannabinoids • present for 1-2 hours after inhalation or ingestion • DOT regulations (impairment: > 5 ng/ml whole blood): can be challenged • Hair cannabinoids + - • unreliable • false positives and negatives from environmental exposure and hair
Load more

Recommended publications
  • Régulation De L'inflammation Par Les Lipides Bioactifs : Interactions Biosynthétiques Et Fonctionnelles Entre Les Endocannabinoïdes Et Les Éicosanoïdes
    Régulation de l'inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Doctorat en microbiologie-immunologie Philosophiæ doctor (Ph. D.) Québec, Canada © Caroline Turcotte, 2019 Régulation de l’inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Sous la direction de : Nicolas Flamand, directeur de recherche Marie-Renée Blanchet, codirectrice de recherche Résumé Les maladies inflammatoires chroniques sont un fardeau de santé important à travers le monde. Les traitements actuellement disponibles soulagent la douleur et l’inflammation, mais leurs effets secondaires rendent leur utilisation à long terme risquée. À la lumière de cette problématique, la communauté scientifique s’intéresse au potentiel d’anti-inflammatoires naturels comme les endocannabinoïdes. Les endocannabinoïdes sont des lipides endogènes qui activent les récepteurs cannabinoïdes (CB1 et CB2). Ils régulent ainsi divers processus physiologiques tels l’appétit, l’adipogénèse et la nociception. Les deux endocannabinoïdes les mieux caractérisés, le 2-AG et l’AEA, peuvent également moduler l’inflammation en activant le récepteur CB2 à la surface des cellules immunitaires. Les souris déficientes pour le récepteur CB2 présentent un phénotype inflammatoire exacerbé, suggérant que ce récepteur est anti-inflammatoire. Cependant, le rôle des endocannabinoïdes dans l’inflammation est beaucoup plus complexe puisqu’ils peuvent être métabolisés en une grande variété de médiateurs lipidiques de l’inflammation. Leur voie de dégradation principale est leur hydrolyse en acide arachidonique (AA), qui sert de précurseur à la biosynthèse d’éicosanoïdes pro-inflammatoires comme le leucotriène B4 et la prostaglandine E2. Ils peuvent également être métabolisés directement par certaines enzymes impliquées dans la synthèse d’éicosanoïdes, pour générer des médiateurs comme les prostaglandines-glycérol (PG-G).
    [Show full text]
  • In Vitro Immunopharmacological Profiling of Ginger (Zingiber Officinale Roscoe)
    Research Collection Doctoral Thesis In vitro immunopharmacological profiling of ginger (Zingiber officinale Roscoe) Author(s): Nievergelt, Andreas Publication Date: 2011 Permanent Link: https://doi.org/10.3929/ethz-a-006717482 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH Nr. 19591 In Vitro Immunopharmacological Profiling of Ginger (Zingiber officinale Roscoe) ABHANDLUNG zur Erlangung des Titels DOKTOR DER WISSENSCHAFTEN der ETH ZÜRICH vorgelegt von Andreas Nievergelt Eidg. Dipl. Apotheker, ETH Zürich geboren am 18.12.1978 von Schleitheim, SH Angenommen auf Antrag von Prof. Dr. Karl-Heinz Altmann, Referent Prof. Dr. Jürg Gertsch, Korreferent Prof. Dr. Michael Detmar, Korreferent 2011 Table of Contents Summary 6 Zusammenfassung 7 Acknowledgements 8 List of Abbreviations 9 1. Introduction 13 1.1 Ginger (Zingiber officinale) 13 1.1.1 Origin 14 1.1.2 Description 14 1.1.3 Chemical Constituents 15 1.1.4 Traditional and Modern Pharmaceutical Use of Ginger 17 1.1.5 Reported In Vitro Effects 20 1.2 Immune System and Inflammation 23 1.2.1 Innate and Adaptive Immunity 24 1.2.2 Cytokines in Inflammation 25 1.2.3 Pattern Recognition Receptors 29 1.2.4 Toll-Like Receptors 30 1.2.5 Serotonin 1A and 3 Receptors 32 1.2.6 Phospholipases A2 33 1.2.7 MAP Kinases 36 1.2.8 Fighting Inflammation, An Ongoing Task 36 1.2.9 Inflammation Assays Using Whole Blood 38 1.3 Arabinogalactan-Proteins 39 1.3.1 Origin and Biological Function of AGPs 40 1.3.2 Effects on Animals 41 1.3.3 The ‘Immunostimulation’ Theory 42 1/188 2.
    [Show full text]
  • To Download the PDF File
    Biological Activities of Selected Dietary Apiaceae, Lamiaceae, and Fabaceae By Huang Huang A Thesis Submitted to the Faculty of Graduate Studies and Research of Carleton University, in partial fulfillment of the requirements for the degree of a Master of Science in Biology Department of Biology Carleton University Ottawa, ON, Canada 2010 © Copyright 2010, Huang Huang i Library and Archives Blbliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de l'6dition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 OttawaONK1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-71582-6 Our file Notre reference ISBN: 978-0-494-71582-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Blbliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Nntemet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • The Role of Cannabinoids in Dermatology
    COMMENTARY The role of cannabinoids in dermatology Jessica S. Mounessa, BS,a,b Julia A. Siegel, BA,c Cory A. Dunnick, MD,a,b and Robert P. Dellavalle, MD, PhD, MSPHa,b Aurora and Denver, Colorado, and Worcester, Massachusetts Key words: cannabinoid; cannabis; dermatitis; endocannabinoid; inflammatory skin disease; keratinocyte carcinoma; melanoma; palmitoylethanolamide; pruritus; skin cancer; tetrahydrocannabinol. wenty-eight states currently allow for Abbreviations used: comprehensive public medical cannabis programs, and this number continues to CB1: cannabinoid 1 T1 CB2: cannabinoid 2 grow. Approximately 1 in 10 adult cannabis users in 2 PEA: palmitoylethanolamide the United States use it for medical purposes. THC: tetrahydrocannabinol Numerous studies have investigated its uses for chronic pain, spasticity, anorexia, and nausea. In recent years, researchers have also investigated its work independently of descending inhibitory use for the treatment of dermatologic conditions pathways.5 including pruritus, inflammatory skin disease, and Cannabinoids may also have anti-inflammatory skin cancer. properties useful for the treatment of both allergic Perhaps the most promising role for cannabinoids contact dermatitis and atopic dermatitis. Petrosino is in the treatment of itch. In a study of patients with et al6 reported that mice released PEA in response to uremic pruritus on maintenance hemodialysis, 2,4-dinitrofluorobenzeneeinduced allergic contact topical application of a cream with structured dermatitis as an endogenous protective agent. PEA physiologic lipids (derma membrane structure) and may work to reduce later stages of allergic contact endogenous cannabinoids applied twice daily for dermatitis, including mast-cell infiltration, angiogen- 3 weeks completely eliminated pruritus in 8 of 21 esis, and itching.7-9 Tetra-hydrocannabinol (THC) patients (38%).
    [Show full text]
  • Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System
    International Journal of Molecular Sciences Review Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System Ana Lago-Fernandez , Sara Zarzo-Arias, Nadine Jagerovic * and Paula Morales * Medicinal Chemistry Institute, Spanish Research Council, Juan de la Cierva 3, 28006 Madrid, Spain; [email protected] (A.L.-F.); [email protected] (S.Z.-A.) * Correspondence: [email protected] (N.J.); [email protected] (P.M.); Tel.: +34-91-562-2900 (P.M.) Abstract: Cannabinoids have shown to exert their therapeutic actions through a variety of targets. These include not only the canonical cannabinoid receptors CB1R and CB2R but also related orphan G protein-coupled receptors (GPCRs), ligand-gated ion channels, transient receptor potential (TRP) channels, metabolic enzymes, and nuclear receptors. In this review, we aim to summarize reported compounds exhibiting their therapeutic effects upon the modulation of CB1R and/or CB2R and the nuclear peroxisome proliferator-activated receptors (PPARs). Concomitant actions at CBRs and PPARα or PPARγ subtypes have shown to mediate antiobesity, analgesic, antitumoral, or neuroprotective properties of a variety of phytogenic, endogenous, and synthetic cannabinoids. The relevance of this multitargeting mechanism of action has been analyzed in the context of diverse pathologies. Synergistic effects triggered by combinatorial treatment with ligands that modulate the aforementioned targets have also been considered. This literature overview provides structural and pharmacological insights for the further development of dual cannabinoids for specific disorders. Citation: Lago-Fernandez, A.; Zarzo-Arias, S.; Jagerovic, N.; Keywords: PPAR; cannabinoids; CB1R; CB2R; FAAH; multitarget; endocannabinoid system Morales, P. Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.
    [Show full text]
  • Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development
    Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 238482, 26 pages http://dx.doi.org/10.1155/2015/238482 Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development Charu Sharma,1 Bassem Sadek,2 Sameer N. Goyal,3 Satyesh Sinha,4 Mohammad Amjad Kamal,5,6 and Shreesh Ojha2 1 Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 2Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 3DepartmentofPharmacology,R.C.PatelInstituteofPharmaceuticalEducation&Research,Shirpur,Mahrastra425405,India 4Department of Internal Medicine, College of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA 5King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia 6Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia Correspondence should be addressed to Shreesh Ojha; [email protected] Received 24 April 2015; Accepted 24 August 2015 Academic Editor: Ki-Wan Oh Copyright © 2015 Charu Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The cannabinoid molecules are derived from Cannabis sativa plant which acts on the cannabinoid receptors types 1 and 2 (CB1 and CB2) which have been explored as potential therapeutic targets for drug discovery and development. Currently, there are 9 numerous cannabinoid based synthetic drugs used in clinical practice like the popular ones such as nabilone, dronabinol, and Δ - tetrahydrocannabinol mediates its action through CB1/CB2 receptors.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]
  • Understanding the Endocannabinoid System
    UNDERSTANDING THE ENDOCANNABINOID SYSTEM (ECS) COMPOUND: Cannabidiol (CBD) CBD is one of approximately 100 phytocannabinoids that are naturally occurring in hemp plants. Cannabinoids refer to molecules found in the cannabis plant that interact with cannabinoid receptors. Common cannabinoids include D9-THC, THCV, CBD, CBDV, CBG and CBC. KEY FACTS: Understanding the ECS • Plays vital neurological and immunomodulatory roles that can affect overall health • Comprised of specialized eicosanoids, known as endocannabinoids, that the body makes from lipid precursors 1. 2. 3. CBCB1 CB2 Endocannabinoids Cannabinoid Enzymes 1. Anandamide Receptors that control 2. 2Arachidonoylglycerol (2AG) endocannabinoid levels This piece is for educational purposes and is intended for review by licensed healthcare practitioners only. This information should not be applied to any particular product offered for sale by company. These therapies are not substitutes for standard medical care. THE ECS IN THE CNS The two major endocannabinoids — anandamide and 2-AG — activate two different cannabinoid receptors: CB1 and CB2. The CB1 receptor is primarily expressed on neurons in the brain and nervous systems; a main function is to inhibit excitatory neurotransmission. Presynaptic neuron Once activated, the CB1 receptor 3 inhibits further release of the stimulating neurotransmitter, Anandamide or 2AG eliciting a relaxant eect. (endocannabinoids) CB Excitatory neurotransmitter 1 (e.g., glutamate) Endocannabinoids 2 activate CB1 receptors, which are located on the presynaptic neuron. CBD increases levels of the endocannabinoid Excitatory neurotransmitters anandamide by inhibiting its reuptake and 1 activate endocannabinoid degradation. As a result, more anandamide synthesis and release. is available to activate cannabinoid receptors. Neurotransmitter receptor The enzyme that CBD modulates is known as FAAH.
    [Show full text]
  • Β-Caryophyllene: a Sesquiterpene with Countless Biological Properties
    applied sciences Review β-Caryophyllene: A Sesquiterpene with Countless Biological Properties 1, 1, 1 1, 1 Fabrizio Francomano y, Anna Caruso y, Alexia Barbarossa , Alessia Fazio *, Chiara La Torre , Jessica Ceramella 1, Rosanna Mallamaci 2 , Carmela Saturnino 3, Domenico Iacopetta 1 and Maria Stefania Sinicropi 1 1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Arcavacata di Rende, Italy; [email protected] (F.F.); [email protected] (A.C.); [email protected] (A.B.); [email protected] (C.L.T.); [email protected] (J.C.); [email protected] (D.I.); [email protected] (M.S.S.) 2 Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via Orabona 4, 70124 Bari, Italy; [email protected] 3 Department of Science, University of Basilicata, 85100 Potenza, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0984-493013 The authors have contributed equally to the manuscript. y Received: 18 November 2019; Accepted: 9 December 2019; Published: 11 December 2019 Abstract: β-Caryophyllene (BCP), a natural bicyclic sesquiterpene, is a selective phytocannabinoid agonist of type 2 receptors (CB2-R). It isn’t psychogenic due to the absence of an affinity to cannabinoid receptor type 1 (CB1). Among the various biological activities, BCP exerts anti-inflammatory action via inhibiting the main inflammatory mediators, such as inducible nitric oxide synthase (iNOS), Interleukin 1 beta (IL-1β), Interleukin-6 (IL-6), tumor necrosis factor-alfa (TNF-α), nuclear factor kapp a-light-chain-enhancer of activated B cells (NF-κB), cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2).
    [Show full text]
  • Clove, an Alternative Medicine Beyond the Spices
    Original Article Reversal of Paracetamol Induced Hepatotoxicity in Animals Model: Clove, an Alternative Medicine beyond the Spices Sadia Kazi, Mashkoor Ahmed Ansari, Ashfaque Rahim Memon, Abdul Rahim Memon, Qamar Zaman Phull ABSTRACT INTRODUCTION: Clove is used as spice commonly and exerts beneficial effects in different human pathologies especially diabetes and infectious diseases discovered in recent times. OBJECTIVE: Current study was aimed to investigate the effects of clove extract on paracetamol induced liver toxicity. METHODOLOGY: This animal study was conducted in Department of pharmacology, Isra University Laboratory Hyderabad and at animal house of veterinary department, Sindh Agriculture University, Tando Jam between September 2013 to October 2013. Through non probability purposive sampling, 30 Rabbits were divided into three groups I, II and III. Acetaminophen 500mg was given to group II and III for 10 days orally, while group I served as control. Group III was co administered 100mg of clove powder for 20 days while group II was started 100mg clove powder on 11th day till 20th day of experiment. All blood samples were taken from ear lobe Base line blood sample before intervention was taken at day 0, then 2nd and 3rd samples were taken at 10 and 20 days respectively after intervention. Liver enzymes were also measured. Data was analyzed on SPSS version 21 using t-test, keeping P-value < 0.05 significant. RESULTS: No significant rise in liver enzymes noticed in group I and group III while all enzymes were increased in group II in initial 10 days but declined back in next 10 days. P-value calculated was 002, 0.001 and 0.001 for ALT,AST and GGT respectively.
    [Show full text]
  • Models Cannabinoid Modulation Effects Alzh Eim Er's D Isease
    Supplementary Table 1 – Modulation of the Endocannabinoid System in pathophysiological conditions. Cannabinoid Models Effects Modulation Microglial cell cultures (mice) + Aβ1-42 JWH-015 ↓ Production of proinflammatory cytokines; ↑ Aβ phagocytosis [243] WIN 55,212-2; JWH-133; Microglia cell cultures (rat) + Aβ1-40 ↓ Microglial activation [275] HU-210 Microglia-neuron co-cultures (rat) + Aβ1-40 WIN 55,212-2; JWH-133 ↓ Microglial induced neurotoxicity by ↑ neuronal survival [275] Hippocampal neuron cultures (rat) + Aβ25-35/Aβ1-42 2-AG; URB602, JZL184 ↓ Neurodegeneration and apoptosis [289] Cortical neuron cultures (rat) + Aβ1-42 ↑ Notch-1 signalling [316] AEA PC12 cells (rat) + Aβ1-40 ↓ Neuronal cell loss [290] PC12 cells (rat) + Aβ1-42 ↑ Cell survival; ↓ ROS production, lipid peroxidation [292] SHSY5Y cell cultures (human) + Aβ1-42 CBD ↓ Aβ neurotoxicity [296] SHSY5Y(APP+) cell cultures (human) ↓ Aβ production; ↑ Cell survival [293] HEK(APP+) cell cultures (human); mixed glia-neuron PPARy activation ↓ APP expression; ↑ Aβ clearance [294,295] cultures (mice) transfected with APPswe mutation Icv Aβ1-42 injection (mice); Intracortical Aβ1-42 injection VDM-11 ↓ Hippocampal neuronal damage (rats); memory impairment (mice) [276] (rats) CBD (mice); WIN 55,212-2 Icv Aβ1-40 injection (mice); Icv Aβ25-35 injection (rats) ↓ Microglial activation; spatial learning/memory impairment [244,275] (rats) Intrahippocampal Aβ1-42 injection (rats) WIN 55,212-2 ↓ Neuroinflammation; spatial learning/memory impairment [298] Intrahippocampal Aβ1-42 injection (rats/mice)
    [Show full text]